Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
COHANCE •NSE
Cohance Lifesciences
₹362.80-15.10 (4.00%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events
Performance
Today’s low
353.15
Today’s high
370.60
52 week low
266.70
52 week high
1,250.00
Open price
364.80
Previous close
377.90
Live volume
56,70,908
Lower circuit
302.35
Upper circuit
453.45
Fundamentals
Market Cap
₹14,467Cr
ROE
10.47%
P/E Ratio(TTM)
55.86
EPS(TTM)
6.77
P/B Ratio
3.82
Dividend Yield
0.00%
Industry P/E
31.90
Book Value
99.01
Debt to Equity
0.12
Face Value
1
Financials
About
Cohance Lifesciences Limited is a contract development and manufacturing organization (CDMO) and API manufacturer.;
MD/CEO
Dr V. Prasada Raju
Founded in
2020
NSE symbol
COHANCE
Industry
Shareholding Pattern
Mar '25
May '25
Jun '25
Sep '25
Dec '25
Mutual Funds Invested (4)
Similar stocks
| Stock | Mkt price (1D) | 52 week performance | Market cap | P/E ratio | P/B ratio | |
|---|---|---|---|---|---|---|
Piramal PharmaPPLPHARMA | ₹147.10 +1.12 (0.77%) | 19,420.32 | -118.78 | 2.4 | ||
Neuland LaboratoriesNEULANDLAB | ₹14,650.00 -301.00 (2.01%) | 19,179.34 | 107.07 | 11.84 | ||
Onesource Specialty PharmaONESOURCE | ₹1,535.00 +96.10 (6.68%) | 16,474.51 | 821.31 | 2.79 | ||
Syngene InternationalSYNGENE | ₹402.35 -2.30 (0.57%) | 16,308.97 | 46.31 | 3.44 |
Livesquawk •
Cohance Life witnessed an NSE block trade of 6,727,880 shares at Rs 309.
The transaction totalled Rs 207.9 crore during the pre-open session.
Livesquawk •
Cohance Life reiterates mid-term margin guidance of 30%+, seeing current margin pressures as timing-related.
Management views margin pressures as temporary, not indicating a structural reset per concall update.
Livesquawk •
Cohance Life has not provided FY27 growth guidance as budget assumptions are being finalized.
Caution is exercised due to FY26 performance, per the company's concall update.
Livesquawk •
Cohance Life maintains $1B sales target for FY30 despite potential timeline shifts.
FY26 challenges may slightly affect achieving the long-term sales goal.
Livesquawk •
Cohance Life forecasts growth in FY27, driven by business pipeline improvements.
Recovery in the API Plus segment is expected to support the growth trajectory.
Livesquawk •
Cohance Life revises FY26 revenue outlook to early-mid double-digit decline.
Concall update confirms adjusted guidance reflecting revenue drop.
Livesquawk •
Cohance Lifesciences' Q3 EBITDA dropped to ₹960M from ₹1.1B YoY.
EBITDA margin fell to 17.6% compared to 38.1% YoY.
2026
12
Feb
Quarterly Result
Release date
2025
12
Nov
Quarterly Result
Release date
13
Aug
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks